Inactive Instrument

Novartis AG Stock Swiss Exchange

Equities

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 11:20:00 2024-07-11 am EDT
99.21 CHF 0.00% Intraday chart for Novartis AG
Sales 2024 * 49.24B 44.08B Sales 2025 * 51.39B 46B Capitalization 227B 203B
Net income 2024 * 10.73B 9.6B Net income 2025 * 12.02B 10.76B EV / Sales 2024 * 4.87 x
Net Debt 2024 * 13.29B 11.9B Net Debt 2025 * 11.62B 10.4B EV / Sales 2025 * 4.64 x
P/E ratio 2024 *
21.3 x
P/E ratio 2025 *
18.4 x
Employees -
Yield 2024 *
3.31%
Yield 2025 *
3.43%
Free-Float 85.22%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company